International Stem Cell Corp. and its subsidiary Lifeline Cell Technology ® have entered into an agreement with Sristi Biosciences for the distribution of the Lifeline brand of human cell culture products in India.
Lifeline develops, manufactures and distributes primary human cells and media and growth factors for optimized culturing of cells, including stem cells. The company notes international requests for its products, including India, one of the fastest growing markets for such products.
Lifeline CEO and senior vice president of Operations at ISCO, Jeffrey Janus, said Sristi Biosciences is highly experienced in advanced cell therapy, and that the company has established a web of professionals and networks that will benefit Lifeline’s plan for growth.
“Sristi Biosciences is part of one of the most experienced biotechnology companies in India and the first to advance cell therapy into human trials in that country. Their network among academic and corporate researchers and experience and capacity to import and handle primary cell cultures, media and growth factors in India will be highly valuable for Lifeline to continue the international commercial expansion of its brand,” Janus stated in the press release.
Lifeline’s is backed by scientists with more than 20 years of experience developing products for the culture of human cells, and sells more than 75 standardized products internationally, directly and through U.S. distributors.
“We are pleased to be the first company to introduce the Lifeline products to the growing Indian research market. Our cell culture experience and broad market reach in India will benefit the brand and help Sristi Biosciences further accelerate its commercialization and corporate growth in the biomedical field,” Dr. Sudhir Reddy, CEO of Sristi Biosciences stated.
ISCO recently announced collaborative efforts with leading Indian eye hospital and research center Sankara Nethralaya regarding ISCO’s human corneal tissue. ISCO also recently signed a Letter of Intent with Insight Bioventures India (IBVI) to obtain funding and to establish and develop manufacturing operations for ISCO India’s research and pharmaceutical products in India.
The agreement with Sristi Biosciences will enhance ISCO’s relationship with IBVI.
“The Lifeline distribution agreement with Sristi Biosciences is central to ISCO’s international expansion. Besides facilitating commercialization of the Lifeline products in India, Sristi Biosciences’ cell therapy development, regulatory and manufacturing expertise will be important as ISCO and IBVI seek to establish ISCO India with cost-efficient development and manufacturing of research and pharmaceutical products for the Indian and broader Asian markets,” Brian Lundstrom, ISCO’s president stated.
For more information visit www.internationalstemcell.com